SecBot SecBot
8-K ·Filed Jun 1, 2026

OTLK

Outlook Therapeutics, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed5mo ago SEC0001104659-26-068659
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

The 60-day PDUFA clock creates a binary catalyst with a defined timeline. The FDA's prior conclusion that no additional trials are needed significantly de-risks approval. Monitor for labeling negotiations and any pre-approval inspection issues. The stock is likely to re-rate toward EU-approved product value ahead of the decision date.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.8430
T+0 close · Jun 1, 2026 · via day close
Latest settled
−24.08%
T+60 · $0.6400
Vs SPY
−25.31%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 1 $0.8430entry
  2. T+1 · 6mo ago −3.44%α −3.58% · $0.8140
  3. T+5 · 5mo ago −7.83%α −5.08% · $0.7770
  4. T+20 · 5mo ago +88.61%α +89.91% · $1.59
  5. T+60 · 3mo ago −24.08%α −25.31% · $0.6400
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Outlook Therapeutics resubmitted its Biologics License Application (BLA) for ONS-5010/LYTENAVA (bevacizumab-vikg) to the FDA for the treatment of neovascular age-related macular degeneration (nAMD). The FDA Office of New Drugs previously concluded that substantial evidence of effectiveness has been established, and this is a Class 1 resubmission with a PDUFA decision expected within 60 days.

Key Facts

  • BLA resubmitted to FDA on June 1, 2026 for ONS-5010/LYTENAVA (bevacizumab-vikg) for nAMD.
  • FDA Office of New Drugs concluded substantial evidence of effectiveness has been established; no additional trials required.
  • Class 1 resubmission with PDUFA decision expected within 60 days of FDA receipt.
  • Product already has Marketing Authorization in the EU and UK; commercial launch commenced in Germany, Austria, and the UK.
  • If approved, ONS-5010 would be the first FDA-approved ophthalmic formulation of bevacizumab.

Financial Impact

No financial figures provided in the filing; market cap is $111M. FDA approval would open the U.S. market for the first on-label ophthalmic bevacizumab, a multi-billion-dollar opportunity in anti-VEGF retinal therapies.

revenuemarket access

Risk Factors

  • FDA could issue a new Complete Response Letter on manufacturing or labeling issues despite the favorable appeal outcome.
  • Pricing and reimbursement in the U.S. may be lower than expected, limiting revenue potential.
  • Competition from existing anti-VEGF agents (Eylea, Vabysmo, Lucentis) and biosimilars may pressure market share.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
78% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-068659
Document: tm2616461d1_ex99-1.htm0001104659-26-068659
Document: 0001104659-26-068659-index-headers.html0001104659-26-068659
Document: 0001104659-26-068659-index.html0001104659-26-068659
Document: 0001104659-26-068659.txt0001104659-26-068659

Track record

37 reports on OTLK

Performance horizon

13 of 22 bullish or bearish reports moved the stock their way by T+5. Best: +306.25% at T+20 after the May 26, 2026 report. 17 of 22 went positive at some point.

Filters
  1. Oct 13, 20264w ago SC 13G Neutral 4/10 Entry $0.5638 to $0.5200 Now $0.3960 −29.76% ▼ −7.77% −6.62% vs SPY
  2. Oct 6, 20265w ago Press Release Neutral 3/10 Entry $0.5720 to $0.5638 Now $0.3960 −30.77% ▼ −1.43% −1.29% vs SPY
  3. Sep 18, 20268w ago 8-K Neutral 3/10 Entry $0.6863 to $0.6211 Now $0.3960 −42.30% ▼ −9.50% −8.48% vs SPY
  4. Aug 14, 202613w ago 8-K Bearish 6/10 Entry $0.7564 to $0.6472 Now $0.3960 +47.65% ▲ +14.44% +13.07% vs SPY
  5. Aug 14, 202613w ago 424B5 Bearish 7/10 Entry $0.7564 to $0.6472 Now $0.3960 +47.65% ▲ +14.44% +13.07% vs SPY
  6. Aug 14, 202613w ago 8-K Bearish 6/10 No price data
  7. Aug 14, 202613w ago Press Release Mixed 7/10 Entry $0.7564 to $0.6472 Now $0.3960 −47.65% ▼ −14.44% −13.07% vs SPY
  8. Aug 12, 202613w ago Press Release Bearish 7/10 Entry $0.8888 to $0.6763 Now $0.3960 +55.45% ▲ +23.91% +21.94% vs SPY
  9. Aug 12, 202613w ago 8-K Bearish 7/10 Entry $0.8888 to $0.6763 Now $0.3960 +55.45% ▲ +23.91% +21.94% vs SPY
  10. Jul 24, 202616w ago 8-K Bullish 8/10 Entry $1.07 to $0.9766 Now $0.3960 −62.82% ▼ −8.30% −9.37% vs SPY
Showing 10 of 37

US Market Status

Market Closed · Opens in 6h 13m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 5, 2026